Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan

 Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan

Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan

Shots:

  • Gilead collaborates with Eisai to distribute & co-promote filgotinib for RA. Gilead will be accountable for manufacturing and approval of filgotinib while Eisai will be responsible for distribution in Japan for RA and other future indications
  • Following the approval, the companies will jointly commercialize filgotinib. The agreement will extend to additional potential indications for filgotinib including UC, CD and PsA
  • Filgotinib is an investigational, oral, selective JAK1 inhibitor with its pending approval for RA in Japan, currently being evaluated in P-III SELECTION, DIVERSITY, PENGUIN study for UC, CD, PsA and P-II studies for uveitis & in the small bowel and fistulizing CD respectively

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Leo Associates

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post